University of California San Francisco Onc Dept
Welcome,         Profile    Billing    Logout  
 13 Trials 
16 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Munster, Pamela N
RENAVIV, NCT03592472 / 2018-001495-38: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Recruiting
3
413
Europe, US, RoW
Pazopanib, Votrient®, Abexinostat, PCI-24781, Placebo
Xynomic Pharmaceuticals, Inc.
Renal Cell Carcinoma
12/24
06/25
NCT04190056: Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

Terminated
2
1
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Tamoxifen, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
University of California, San Francisco, Merck Sharp & Dohme LLC
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
06/23
06/23
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Completed
1/2
169
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
11/24
12/24
ATLAS-101, NCT04503265: A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Recruiting
1/2
122
US
AMXI-5001:Dose Escalation Phase I, Phase I, Dose Escalation, AMXI-5001:Dose Expansion Phase II, Phase II, Dose Expansion
AtlasMedx, Incorporated
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
08/26
10/26
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients With Advanced Solid Tumors

Recruiting
1/2
378
Europe, US
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
Biolen-PC, NCT04284761: A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Completed
1
17
US, RoW
Bicalutamide implant
Alessa Therapeutics Inc.
Prostate Adenocarcinoma, Lower Urinary Tract Symptoms
05/23
05/23
NCT04257110: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Active, not recruiting
1
208
US, RoW
BB-1701
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Locally Advanced/Metastatic HER2 Positive Solid Tumors
08/24
12/24
NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended
1
71
US
JSI-1187, Dabrafenib, TAFINLAR
JS InnoPharm, LLC
Solid Tumors
06/24
12/24
NCT04678648: A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Recruiting
1
134
US
RSC-1255 Dose Escalation, Phase 1a, Dose Escalation, RSC-1255 Dose Expansion, Phase 1b, Dose Expansion
RasCal Therapeutics, Inc.
Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
07/25
09/25
NCT01543763: Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
More
Active, not recruiting
1
90
US
PZP115891, PCI-24781, abexinostat, S 78454, GW786034, Votrient™, Pazopanib
Pamela Munster, Pharmacyclics LLC., Novartis, Xynomic Pharmaceuticals, Inc., GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
Metastatic Solid Tumors
01/24
12/24
NCT04774952: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Active, not recruiting
1
108
US
RMC-5552
Revolution Medicines, Inc.
Solid Tumors
03/24
03/24
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, pembrolizumab, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
05/29
05/29
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
NCT05694715: Combination Therapy in Cancers With Mutations in DNA Repair Genes

Recruiting
1
24
US
Niraparib, Zejula, Small molecule inhibitor, Irinotecan, Camptosar, Irinotecan hydrochloride, CPT-11
University of California, San Francisco, GlaxoSmithKline
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
01/28
01/28
Cockerill, Alyson
No trials found

Download Options